To reach the next value inflection
LicenseRx asset brief
Genome Wide DNase I Hypersensitive Sites Detection in Formalin-Fixed Paraffin-Embedded Single Cells
Probability of Success
15% · grade C · Medium data confidence
Model PoS 15% (grade C, medium data confidence). Strongest signals: Indication pull, Modality feasibility. Biggest drag: IP position.
Data maturity (22%)
36
Early / Discovery; limited public evidence of validation.
IP position (16%)
30
Protection lapsed or abandoned -- verify freedom to operate.
Modality feasibility (14%)
80
Diagnostic/biomarker -- can monetize via service before full approval.
Indication pull (14%)
82
Oncology -- active buyer appetite.
Competitive whitespace (12%)
72
Under-served segment; crowded oncology field.
Translational evidence (12%)
54
Public evidence mentions: patient.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →